Cancidas and Hepatitis aggravated - a phase IV clinical study of FDA data


Hepatitis aggravated is found among people who take Cancidas, especially for people who are male, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Cancidas and have Hepatitis aggravated. It is created by eHealthMe based on reports of 4,415 people who have side effects when taking Cancidas from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 30, 2022

4,415 people reported to have side effects when taking Cancidas.
Among them, 39 people (0.88%) have Hepatitis aggravated.

What is Cancidas?

Cancidas has active ingredients of caspofungin acetate. eHealthMe is studying from 4,425 Cancidas users for its effectiveness, alternative drugs and more.

What is Hepatitis aggravated?

Hepatitis aggravated is found to be associated with 595 drugs and 284 conditions by eHealthMe.

Number of Cancidas and Hepatitis aggravated reports submitted per year:

Could Cancidas cause Hepatitis aggravated?

Time on Cancidas when people have Hepatitis aggravated *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatitis aggravated when taking Cancidas *:

  • female: 43.59 %
  • male: 56.41 %

Age of people who have Hepatitis aggravated when taking Cancidas *:

  • 0-1: 0.0 %
  • 2-9: 7.89 %
  • 10-19: 0.0 %
  • 20-29: 5.26 %
  • 30-39: 26.32 %
  • 40-49: 5.26 %
  • 50-59: 42.11 %
  • 60+: 13.16 %

Common drugs people take besides Cancidas *:

  1. Pantoprazole: 6 people, 15.38%
  2. Bactrim: 6 people, 15.38%
  3. Vancomycin: 5 people, 12.82%
  4. Acyclovir: 4 people, 10.26%
  5. Cyclosporine: 4 people, 10.26%
  6. Augmentin: 3 people, 7.69%
  7. Ciprofloxacin: 3 people, 7.69%
  8. Diflucan: 3 people, 7.69%
  9. Doribax: 3 people, 7.69%
  10. Heparin Sodium: 3 people, 7.69%

Common side effects people have besides Hepatitis aggravated *:

  1. Encephalopathy (functioning of the brain is affected by some agent or condition): 9 people, 23.08%
  2. Hepatic Failure (liver failure): 7 people, 17.95%
  3. Rashes (redness): 4 people, 10.26%
  4. Hyperbilirubinaemia (excess of bilirubin in the blood): 3 people, 7.69%
  5. Pancreatitis (inflammation of pancreas): 3 people, 7.69%
  6. Pleural Effusion (water on the lungs): 3 people, 7.69%
  7. Multi-Organ Failure (multisystem organ failure): 3 people, 7.69%
  8. Ascites (accumulation of fluid in the abdominal cavity): 2 people, 5.13%
  9. Pneumonia: 2 people, 5.13%
  10. Bleeding Disorders: 2 people, 5.13%

Common conditions people have *:

  1. Infection: 6 people, 15.38%
  2. Septic Shock (shock due to blood infection): 4 people, 10.26%
  3. Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream): 3 people, 7.69%
  4. Septic Embolus (a type of embolism that is infected with bacteria): 3 people, 7.69%
  5. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 7.69%
  6. Respiratory Tract Infection: 3 people, 7.69%
  7. Febrile Neutropenia (fever with reduced white blood cells): 3 people, 7.69%
  8. Fungaemia (fungi circulate in the blood): 3 people, 7.69%
  9. Oral Herpes (viral infection of mouth): 3 people, 7.69%
  10. Heart Disease: 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Cancidas and have Hepatitis aggravated?

Check whether Hepatitis aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of Cancidas:

Hepatitis aggravated treatments and more:

COVID vaccines that are related to Hepatitis aggravated:

How severe was Hepatitis aggravated and when was it recovered:

Expand to all the drugs that have ingredients of caspofungin acetate:

Common drugs associated with Hepatitis aggravated:

All the drugs that are associated with Hepatitis aggravated:

Common conditions associated with Hepatitis aggravated:

All the conditions that are associated with Hepatitis aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on caspofungin acetate (the active ingredients of Cancidas) and Cancidas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: